Bavencio Fails to Meet Primary Objectives in Certain Ovarian Cancer Patients in Phase 3 Trial

Bavencio Fails to Meet Primary Objectives in Certain Ovarian Cancer Patients in Phase 3 Trial
The immune checkpoint inhibitor Bavencio (avelumab), with or without chemotherapy, is no better than chemotherapy alone at prolonging the lives of ovarian cancer patients who failed prior platinum-based chemotherapy, results from a Phase 3 trial suggest. The trial (NCT02580058), called JAVELIN Ovarian 200, which tested Bavencio alone or in combination with pegylated liposomal doxorubicin (PLD), versus PLD alone, also failed to show a delay in disease progression or death among Bavencio-treated patients, failing to meet both its primary goals. Further analyses of the trial results are now being conducted and will be shared with the scientific community at a later date, according to Merck KGaA (which operates as EMD Serono in the U.S. and Canada) and Pfizer, who jointly developed the therapy. “Although [overall survival] and [progression-free survival] did not reach statistical significance, study results indicate potential clinical activity of the combination of avelumab and chemotherapy which will be analyzed further," said Luciano Rossetti, MD, executive vice president, global head of research and development at the biopharma business of Merck KGaA, said in a press release. Rossetti thanked the patients, their families, and the investigators
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *